Publications by authors named "Angel Fowler Taylor"

Claim this Profile
B
Bioequivalence Between a New Omalizumab Prefilled Syringe With an Autoinjector or with a Needle Safety Device Compared with the Current Prefilled Syringe: A Randomized Controlled Trial in Healthy Volunteers.
Ramachandra Sangana, Yan Xu, Bharti Shah, Xianbin Tian, Julia Zack, Angel Fowler Taylor

Clin Pharmacol Drug Dev· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Maintenance Bronchodilation With Indacaterol/Glycopyrrolate Versus Indacaterol in Moderate-to-Severe COPD Patients: The FLIGHT 3 Study.
Gary T Ferguson, Angel Fowler Taylor, Chau Thach, Qian Wang, Agnes A Schubert-Tennigkeit

Chronic Obstr Pulm Dis· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease.
Donald A Mahler, Edward Kerwin, Tim Ayers, Angel FowlerTaylor, Samopriyo Maitra

Am J Respir Crit Care Med· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
QVA149 versus glycopyrronium for COPD - authors' reply.
Jadwiga A Wedzicha, Marc Decramer, Joachim H Ficker, Dennis E Niewoehner, Thomas Sandström, Angel Fowler Taylor

Lancet Respir Med· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study.
Jadwiga A Wedzicha, Marc Decramer, Joachim H Ficker, Dennis E Niewoehner, Thomas Sandström, Angel Fowler Taylor

Lancet Respir Med· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma.
Henry Milgrom, Angel Fowler-Taylor, Carlos Fernandez Vidaurre, Sumedha Jayawardene

Curr Med Res Opin· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma.
Bob Lanier, Tracy Bridges, Marek Kulus, Angel Fowler Taylor, Indrias Berhane

J Allergy Clin Immunol· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.
Ratko Djukanović, Susan J Wilson, Monica Kraft, Nizar N Jarjour, Mark Steel, Angel Fowler-Taylor

Am J Respir Crit Care Med· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis.
Anjuli Nayak, Thomas Casale, S David Miller, John Condemi, Margaret McAlary, Angel Fowler-Taylor

Allergy Asthma Proc· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omalizumab is effective in the long-term control of severe allergic asthma.
Bobby Quentin Lanier, Jonathan Corren, William Lumry, Jeen Liu, Angel Fowler-Taylor

Ann Allergy Asthma Immunol· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis.
Paul Chervinsky, Thomas Casale, Robert Townley, Ita Tripathy, Simon Hedgecock, Angel Fowler-Taylor

Ann Allergy Asthma Immunol· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma.
William Berger, Niroo Gupta, Margaret McAlary, Angel Fowler-Taylor

Ann Allergy Asthma Immunol· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omalizumab improves asthma-related quality of life in patients with severe allergic asthma.
Albert Finn, Gary Gross, Julius van Bavel, Theodore Lee, Hugh Windom, Angel Fowler-Taylor

J Allergy Clin Immunol· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omalizumab improves asthma-related quality of life in children with allergic asthma.
Robert F Lemanske, Anjuli Nayak, Margaret McAlary, Francois Everhard, Angel Fowler-Taylor

Pediatrics· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis